Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-438 PK interaction with Clarithromycin
NCT02774902Phase 1Completed
- Sponsor
- Takeda
- Start
- Aug 2010
- Primary completion
- Sep 2010
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of vonoprazan in gastroesophageal reflux disease (GERD), Peptic ulcer disease (PUD) and Helicobacter pylori infection, sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration at Day 8, Area Under the Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Concentration at Day 8 and 2 more. Started Aug 2010; status: completed.
02
Drugs
vonoprazan
03
Conditions
gastroesophageal reflux disease (GERD)Peptic ulcer disease (PUD)Helicobacter pylori infection
Beyond the preview
Go deeper on NCT02774902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02774902.